ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / ASBP
CLRB (32) LSTA (29) GTBP (36) LPCN (23) ⌘ Pro Terminal →

Aspire-Lakewood Holdings Inc. (ASBP) — RQD Stock Rating Cockpit

$7.30 -9.99% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $7.15

Aspire-Lakewood Holdings Inc. (ASBP) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $11.4M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ASBP Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ASBP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Aspire-Lakewood Holdings Inc. (NASDAQ: ASBP) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $7.30 (-9.99% 1D, market cap $11.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ASBP ranks #474 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ASBP compare to CLRB and LSTA in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ASBP carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of -1.9%, and ROIC of -35.0%. By comparison, CLRB (Cellectar Biosciences Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $11.4M) and LSTA (Lisata Therapeutics Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $11.0M). Among the 5-stock peer group, ASBP leads on earnings multiple (N/A) while ASBP leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ASBP?
▼

Per ASBP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001847345), Aspire-Lakewood Holdings Inc. generated $6.2K in revenue (-99.8% YoY), -$24.5M in net income, and -$4.9M in free cash flow against $1.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $7.15 (-1.99%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510040
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (8)Whales (9)SEC (8)Macro (12)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-8.1% Base Target
$16 Bull$7 Base$5 Bear
📬 FREE ASBP RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ASBP)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (40/100 Composite)
🔍 WHY ASBP SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+12/20 pts (30% of score)

FRED Regime × Technicals: 46% of 52W Range • RSI-14 at 45.7 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+9/20 pts (23% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
48
Grade D$8.18+6.6% Next Q
Q2 (-2Q)
45
Grade D$8.72-3.2% Next Q
Q3 (-1Q)
43
Grade D$8.44-13.5% Next Q
Current
40
Grade D-$7.30-7.4% Hist 90D α
Trajectory: D (48) → D- (40)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ASBP Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ASBP currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($8.57) and Max Pain ($7.67) forces dealer call-delta covering toward $16.38.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ASBP• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ASBP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 40%NO 60%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
45.730 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
1 / 99-Pt Accounting
52-WEEK LASER RANGE46% OF RANGE
L: $0$7.30H: $16
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 12 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 20 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on ASBP

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (40)

-35.0% ROIC with -1.9% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (40)

Altman-Z 4.20 and Piotroski 1/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (40)

12/40 institutional & smart-money positioning score with 12/20 macro alignment.

Bull Case: Why Buyers Like ASBP
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ASBP)

  • ✓Walkthrough of ASBP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ASBP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +3376.19%🛡️ HOLDING TREND SUPPORT
2026-11-03O $8.48H $8.48L $7.30C $7.30VOL 20.3K
RES: $9.11SUP: $6.48SMA50: $8.57SMA200: $4.88
$10.16$7.43$4.71$1.99$-0.74RES $9.11SUP $6.48$7.302026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ASBP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ASBP Butterfly Map → + Track ASBP →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -99.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ASBP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ASBP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ASBP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ASBP)

Health Care Rank #474 of 1015 ⚔️ CLRB vs ASBP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ASBP vs. CLRB, LSTA, GTBP, LPCN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Aspire-Lakewood Holdings Inc. (ASBP) ranks #474 by composite RQD confidence (40/100, grade D-) and #881 by equity capitalization ($11.4M). Within this direct 5-issuer industry benchmark cohort, ASBP leads on earnings valuation at N/A trailing P/E, while ASBP leads on capital efficiency and profitability with -35.0% ROIC and -1.9% gross margin. ASBP currently leads its immediate peer cohort in composite quantitative strength at 40/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ASBP ACTIVE
Aspire-Lakewood Holdings Inc.
D- 40/100 — -1.9% -35.0% -9.99% $11.4M Benchmark Subject
CLRB
Cellectar Biosciences Inc.
E 32/100 — — -35.0% +1.25% $11.4M /clrb-vs-asbp →
LSTA
Lisata Therapeutics Inc.
E 29/100 — — -35.0% -0.98% $11.0M /lsta-vs-asbp →
GTBP
GT Biopharma Inc.
D- 36/100 — — -35.0% -3.57% $11.0M /gtbp-vs-asbp →
LPCN
Lipocine Inc.
E 23/100 — — -35.0% +0.69% $11.9M /lpcn-vs-asbp →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001847345 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Aspire-Lakewood Holdings Inc. (ASBP) reported GAAP revenue of $6.2K (-99.8% vs. FY2024 revenue of $3.4M , and -100.0% cumulative change since FY2023) , GAAP net income of -$24.5M, operating cash flow of -$4.9M, and free cash flow of -$4.9M (-1756.6% YoY). On the balance sheet, ASBP closed FY2025 with $1.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $6.2K -$24.5M -$4.9M -$4.9M $1.3M —
FY2024 (FY) 2024-12-31 $3.4M -$1.3M -$265.2K -$265.2K $148.0K —
FY2023 (FY) 2023-12-31 $20.1M $4.5M -$653.1K -$653.1K — —

3. ASBP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ASBP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Aspire-Lakewood Holdings Inc. (NASDAQ: ASBP) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $7.30 (-9.99% 1D, market cap $11.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, ASBP ranks #474 in composite RQD confidence.

How does ASBP compare to CLRB and LSTA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ASBP carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of -1.9%, and ROIC of -35.0%. By comparison, CLRB (Cellectar Biosciences Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $11.4M) and LSTA (Lisata Therapeutics Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $11.0M). Among the 5-stock peer group, ASBP leads on earnings multiple (N/A) while ASBP leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ASBP?

Per ASBP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001847345), Aspire-Lakewood Holdings Inc. generated $6.2K in revenue (-99.8% YoY), -$24.5M in net income, and -$4.9M in free cash flow against $1.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ASBP trading relative to its 50-day, 200-day, and 52-week technical levels?

ASBP last traded at $7.30 (-9.99% on volume of 21,021 shares), positioning the stock -14.82% below its 50-day simple moving average ($8.57) and +49.59% above its 200-day simple moving average ($4.88). Across its 52-week range of $0.11 to $15.60, ASBP sits at the 46.4% percentile with a 14-day RSI of 45.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($6.39 to $8.21).

Direct Sub-Reports: ASBP RQD Cockpit ASBP 12M Forecast ASBP Earnings & Move ASBP Dividends & DRIP ASBP Insiders & 13F ASBP Whale Options ASBP Profit Sankey ASBP News & Why
ROARABLE RATING BRIEF • RQD 40/100 (D-) ✓ SEC XBRL & RQD VERIFIED

ASBP — Aspire-Lakewood Holdings Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Aspire-Lakewood Holdings Inc. (ASBP) earns a live Roarable RQD composite score of 40/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $7.30 (-9.99% 1D, market capitalization $11.4M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of -1.9%, operating margin of -60.0%, and free cash flow yield of —.
  • Whale 13F & Options Flow (9/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (12/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Aspire-Lakewood Holdings Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Pharmaceutical Preparations. — for product lines, customers, or revenue model.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Aspire-Lakewood Holdings Inc. (ASBP) reported $6.2K in annual revenue (up from $3.4M in FY2024, -99.8% YoY) and -$24.5M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($20.1M revenue, $4.5M net income) through FY2025, ASBP scaled operating cash flow to -$4.9M and free cash flow to -$4.9M, backed by $1.3M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 40/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 9/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 9/20, sustained execution supports upside toward the upper end of the $0.11 – $15.60 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

There are no upstream or downstream links and no proprietary signals. — for upstream dependencies, downstream customers, or sector correlations.

  • Key Question #1: Can ASBP sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $6.2K and free cash flow of -$4.9M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is ASBP's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ASBP Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Aspire-Lakewood Holdings Inc. (ASBP) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ASBP Debate Forum (3) ↓
🟢 CATALYST Yahoo Finance • 144d ago
Aspire Biopharma Announces Signing of Definitive Share Purchase Agreement to Acquire Dura Driver Control Systems, a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 Revenue

Adds an established global brand with scale in large and growing markets driven by trends in vehicle and mobility control systems Acquisition significantly accelerates Aspire's revenue, earnings growth and cash flow prof

Read Full Source ↗
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ASBP Bull vs. Bear Conversation Board — What's Your Call at $7.30?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ASBP 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ASBP:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $10.62 (+30.9%)
📌 Pinned Debate

Institutional accumulation and options positioning support a 10/20 whale-flow pillar, and beta of 1.0 gives the stock market-level sens

Don't sleep on ASBP's setup in Health Care. Institutional accumulation and options positioning support a 10/20 whale-flow pillar, and beta of 1.0 gives the stock market-level sensitivity to any sector recovery.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (40/100) backs up the fundamental quality.

RetailWhale_TX 🐂 BULL

Both sides have a point here — ASBP's 8/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $6.89 (-15.0%)
Spot @ $8.11

Negative ROIC of -35%, zero FCF yield, Piotroski F-Score of 1/9, and a -60% net margin leave the business without fundamental cash supp

Sitting on the sidelines or leaning short ASBP above $8.11. Negative ROIC of -35%, zero FCF yield, Piotroski F-Score of 1/9, and a -60% net margin leave the business without fundamental cash support.. Until Fundamental Cash Engine (8/20) and FCF yield (0.0%) inflect higher, upside is capped near $15.60.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%